Pancreatic duct

ConcertAI's TeraRecon Launches Three New Care Suites, Life Sciences Platform, and Strategic Partnerships at #ECR24

Retrieved on: 
Monday, February 26, 2024
MRI, CE, Algorithm, Radiology, Doctor of Philosophy, AI, Research, Gen, Intuition, Extrapyramidal system, FDA, Cardiology, Generative, Integration, Workflow, Bone fracture, Synthetic media, ECR, Software as a service, KLAS, Pancreatic duct, Genomics, Multi, Prostate cancer, Medical imaging

CAMBRIDGE, Mass., Feb. 26, 2024 /PRNewswire/ -- ConcertAI's TeraRecon, the #1 KLAS-ranked advanced visualization and AI Clinical SaaS solution, has announced that European healthcare providers now have access to its cardiology, pulmonology, and neurology suites. In addition, the company initiated new partnerships with several leading CE-marked AI software developers, including Gleamer, Lucida Medical, and Perspectum. TeraRecon now provides a leading unified solution for clinical AI algorithms in Europe across radiology, neurology, oncology, pulmonology, and cardiology.

Key Points: 
  • In addition, the company initiated new partnerships with several leading CE-marked AI software developers, including Gleamer, Lucida Medical, and Perspectum.
  • TeraRecon now provides a leading unified solution for clinical AI algorithms in Europe across radiology, neurology, oncology, pulmonology, and cardiology.
  • Outside the show floor, TeraRecon and Perspectum will present an AI Lightning Talk, titled Integrating AI in Clinical Care on Friday March 1st @ 12:50PM.
  • This first-in-class platform seamlessly integrates Intuition advanced visualization, TeraRecon clinical AI imaging solutions, digital pathology, genomics, and electronic medical record derived clinical data.

ConcertAI's TeraRecon Launches Three New Care Suites, Life Sciences Platform, and Strategic Partnerships at #ECR24

Retrieved on: 
Monday, February 26, 2024
MRI, CE, Algorithm, Radiology, Doctor of Philosophy, AI, Research, Gen, Intuition, Extrapyramidal system, FDA, Cardiology, Generative, Integration, Workflow, Bone fracture, Synthetic media, ECR, Software as a service, KLAS, Pancreatic duct, Genomics, Multi, Prostate cancer, Medical imaging

CAMBRIDGE, Mass., Feb. 26, 2024 /PRNewswire/ -- ConcertAI's TeraRecon, the #1 KLAS-ranked advanced visualization and AI Clinical SaaS solution, has announced that European healthcare providers now have access to its cardiology, pulmonology, and neurology suites. In addition, the company initiated new partnerships with several leading CE-marked AI software developers, including Gleamer, Lucida Medical, and Perspectum. TeraRecon now provides a leading unified solution for clinical AI algorithms in Europe across radiology, neurology, oncology, pulmonology, and cardiology.

Key Points: 
  • In addition, the company initiated new partnerships with several leading CE-marked AI software developers, including Gleamer, Lucida Medical, and Perspectum.
  • TeraRecon now provides a leading unified solution for clinical AI algorithms in Europe across radiology, neurology, oncology, pulmonology, and cardiology.
  • Outside the show floor, TeraRecon and Perspectum will present an AI Lightning Talk, titled Integrating AI in Clinical Care on Friday March 1st @ 12:50PM.
  • This first-in-class platform seamlessly integrates Intuition advanced visualization, TeraRecon clinical AI imaging solutions, digital pathology, genomics, and electronic medical record derived clinical data.

Genprex Signs Exclusive License to Additional Diabetes Technology with the University of Pittsburgh

Retrieved on: 
Tuesday, July 18, 2023
C-peptide, Insulin, Human, MAFB (gene), University, Pediatrics, Diabetes, Pancreas, Cancer, Pitt, University of Pittsburgh School of Medicine, AAV, Patent, MD, Patient, Division, Immune system, Pancreatic duct, MAF (gene), NHP, Wilfrid Sellars, Gene, PDX1, Disease, Pharmaceutical industry

AUSTIN, Texas, July 18, 2023 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced it has entered into an exclusive license agreement with the University of Pittsburgh (Pitt), granting Genprex a worldwide, exclusive license to a patent application and related technology and a worldwide, non-exclusive license to use certain related know-how, all related to a gene therapy for both Type 1 and Type 2 diabetes using the genes of the Pdx1 and MafA transcription factors controlled by a MafB promoter. 

Key Points: 
  • "We are continuing to build a fortress of protection and a powerful intellectual property portfolio for our diabetes gene therapy program.
  • The addition of this license to MafB promoter technology expands and strengthens the potential for this novel, gene therapy to treat Type 1 and Type 2 diabetes," said Rodney Varner, Chairman, President and Chief Executive Officer at Genprex.
  • "In licensing this latest exclusive technology, which joins several others that provide us with multiple diabetes gene therapy combinations, we have valuable rights over what we believe are the most innovative, emerging diabetes gene therapies."
  • Earlier this year, the Company's research collaborators at the University of Pittsburgh presented preclinical data in a Non-Human Primate (NHP) model of Type 1 diabetes highlighting the therapeutic potential of GPX-002.

Perspectum Completes $36 Million First Close of Series C Funding Led by Oppenheimer Holdings

Retrieved on: 
Thursday, January 5, 2023
Software, Radiology, Oncology, Health, Artificial Intelligence, Medical Devices, Health Technology, Technology, Cancer, Standard of care, MRI, Microsoft, Medicare, MD, Multimedia, Inflammation, Series, Oppenheimer Holdings, Pancreatic duct, Patient, Physician, FDA, Hospital, Oppenheimer, Conditional sentence, Diagnosis, Doctor of Philosophy, Magnetic resonance imaging, Biopsy, Pharmaceutical industry, Medical imaging, Nuance

Perspectum, a precision health company which develops medical imaging tools to improve the diagnoses of metabolic diseases and cancer, has completed the first close of its Series C funding round.

Key Points: 
  • Perspectum, a precision health company which develops medical imaging tools to improve the diagnoses of metabolic diseases and cancer, has completed the first close of its Series C funding round.
  • The new $36 million investment was led by Oppenheimer Holdings.
  • The Series C funding brings the total amount raised since inception to circa $120 million.
  • Perspectum is working to expand its footprint across the country and grow its customer base.

Scala Announces a Major Release of Flagship Digital Signage Platform Scala Enterprise 13.00

Retrieved on: 
Thursday, December 8, 2022
Pancreatic duct, LINQ, Transport, Environment, Microsoft Windows, HTML, Investment, Product management, Tablet, Restaurant, Multimedia, Hotel manager, Marketing, Linux, Motivation, Video game console, Mobile phone, Scala

MALVERN, Pa., Dec. 8, 2022 /PRNewswire/ --Scala today announced the release of its flagship digital signage platform, Scala Enterprise version 13.00, a major release that introduces a number of highly requested features into the product.

Key Points: 
  • MALVERN, Pa., Dec. 8, 2022 /PRNewswire/ --Scala today announced the release of its flagship digital signage platform, Scala Enterprise version 13.00, a major release that introduces a number of highly requested features into the product.
  • Scala, part of the STRATACACHE family of technology companies, continues to add significant investments to enhance the digital signage platform for more than 16,000 clients in stores, restaurants, transportation hubs, corporate campuses and more.
  • "The motivation behind the content chosen for Scala Enterprise R13.00 was two-fold."
  • Highlights of Scala Enterprise 13.00:
    The Windows 64-bit player engine is available for new installation and upgrades for players in the network.

Scala Announces a Major Release of Flagship Digital Signage Platform Scala Enterprise 13.00

Retrieved on: 
Thursday, December 8, 2022
Pancreatic duct, LINQ, Transport, Microsoft Windows, Environment, HTML, Investment, Product management, Tablet, Restaurant, Hotel manager, Marketing, Linux, Motivation, Video game console, Scala

MALVERN, Pa., Dec. 8, 2022 /PRNewswire/ --Scala today announced the release of its flagship digital signage platform, Scala Enterprise version 13.00, a major release that introduces a number of highly requested features into the product.

Key Points: 
  • MALVERN, Pa., Dec. 8, 2022 /PRNewswire/ --Scala today announced the release of its flagship digital signage platform, Scala Enterprise version 13.00, a major release that introduces a number of highly requested features into the product.
  • Scala, part of the STRATACACHE family of technology companies, continues to add significant investments to enhance the digital signage platform for more than 16,000 clients in stores, restaurants, transportation hubs, corporate campuses and more.
  • "The motivation behind the content chosen for Scala Enterprise R13.00 was two-fold."
  • Highlights of Scala Enterprise 13.00:
    The Windows 64-bit player engine is available for new installation and upgrades for players in the network.

Perspectum Announces American Medical Association (AMA) Issues Two Unique Category III CPT® Codes Priced Appropriately by the Centers for Medicare & Medicaid Services (CMS) for Noninvasive Biliary Anatomy Assessment With MRCP+

Retrieved on: 
Tuesday, July 5, 2022
Health Technology, Health, Medical Devices, Centers for Medicare & Medicaid Services, Diagnosis, MRCP, Biliary disease, Patient, American Medical Association, Precision medicine, European Association for the Study of the Liver, CMS, AMA, Anatomy, Center, EASL, Internal medicine, Cancer, Primary biliary cholangitis, AGAF, Association, Gallbladder, Cholestasis, Category, Liver disease, PSC, CPT, FACP, ERCP, Primary sclerosing cholangitis, Magnetic resonance cholangiopancreatography, Health, Pediatrics, Pancreatic duct, Genetics, Medicare, Physician, MD, MRI, Baylor College of Medicine, Hospital, Medical imaging, Medicaid, Liver

Effective July 1, 2022, the Centers for Medicare & Medicaid Services (CMS) has issued appropriate reimbursement for the MRCP+ procedure.

Key Points: 
  • Effective July 1, 2022, the Centers for Medicare & Medicaid Services (CMS) has issued appropriate reimbursement for the MRCP+ procedure.
  • CPT 0723T has been assigned to APC 1511 New Technology Level 11, reimbursement range $900-$1000, effective July 1, 2022.
  • MRCP+ is an image analysis tool that enhances MRCP data to provide visualization and quantitative assessment of the biliary system.
  • The guidelines reference MRCP+ as a novel technique to automatically segment biliary anatomy and provide quantitative biliary tree metrics.

Global Pancreatic and Biliary stent (General Surgery) Market Analysis and Forecast Report 2022-2030 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 16, 2022
Surgery, Health, Medical Devices, Gallbladder, ERCP, Obstruction, SWOT, Market access, Region, Country, Forecast model, Pancreas, Review, General surgery, COVID-19, Stent, Pancreatitis, Pancreatic duct, General officer, Percutaneous transhepatic cholangiography, PTC, Epidemiology, Bile, Jaundice, Industry, Medical imaging, Retail, Healthcare

The "Pancreatic and Biliary stent (General Surgery) - Global Market Analysis and Forecast Model" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Pancreatic and Biliary stent (General Surgery) - Global Market Analysis and Forecast Model" report has been added to ResearchAndMarkets.com's offering.
  • Pancreatic and Biliary stent (General Surgery) - Global Market Analysis and Forecast Model (COVID-19 Market Impact) is built to visualize quantitative market trends within General Surgery therapeutic area.
  • The model discusses in detail the impact of COVID-19 on Pancreatic and Biliary Stents market for the year 2020 and beyond.
  • The Pancreatic and biliary stents market is mainly driven by the diseases resulting in the obstruction in bile or pancreatic ducts.

NCCN Expands Resources for Treating Rare Cancer Types

Retrieved on: 
Wednesday, March 9, 2022
Consensus, Survival, Lung, Duodenum, Patient, Degenerative disease, Health, Approximation error, Pancreatic duct, Virtual, Consensus decision-making, Peritoneum, Abdomen, Ward E. Pack, EDS, Safety, National Comprehensive Cancer Network, Biliary tract, Colon, National Cancer Institute, Ovarian cancer, Malignancy, Cancer, NCCN, Decision-making, Recurrence, DS, Squamous cell carcinoma, Prostate, Research, BMC, BMC Cancer, Journal of the National Comprehensive Cancer Network, Prognosis, Pancreas, SEER, Policy, USS William M. Wood (DE-287), Caregiver, Medicine, Twitter, Breast, Education, Veni, vidi, vici, Immunotherapy, Amazon (company), Farstad Shipping, Risk management, Dietary supplement, Medical imaging, Medical device, Silviculture, Vaccine, MD

PLYMOUTH MEETING, Pa., March 9, 2022 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers—today announced the publication of new NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Ampullary Adenocarcinoma. This evidence- and expert consensus-based resource follows the recent publication of new NCCN Guidelines® for Malignant Peritoneal Mesothelioma, bringing the total number of clinical guidelines to 83.

Key Points: 
  • PLYMOUTH MEETING, Pa., March 9, 2022 /PRNewswire/ --The National Comprehensive Cancer Network (NCCN)an alliance of leading cancer centerstoday announced the publication of new NCCN Clinical Practice Guidelines in Oncology ( NCCN Guidelines ) for Ampullary Adenocarcinoma .
  • NCCN Guidelines are available free-of-charge for non-commercial use at NCCN.org or via the Virtual Library of NCCN Guidelines App .
  • Newly-posted NCCN Guidelines for Patients: Systemic Mastocytosis (a rare mast cell disorder) and updated NCCN Guidelines for Patients: Small Cell Lung Cancer are available as a free download at NCCN.org/patientguidelines or the NCCN Patient Guides for Cancer App , or printed for a nominal fee via Amazon.com.
  • The National Comprehensive Cancer Network ( NCCN ) is a not-for-profit alliance of leading cancer centers devoted to patient care, research, and education.

NCCN Expands Resources for Treating Rare Cancer Types

Retrieved on: 
Wednesday, March 9, 2022
Consensus, Survival, Lung, Duodenum, Patient, Degenerative disease, Health, Approximation error, Pancreatic duct, Virtual, Consensus decision-making, Peritoneum, Abdomen, Ward E. Pack, EDS, Safety, National Comprehensive Cancer Network, Biliary tract, Colon, National Cancer Institute, Ovarian cancer, Malignancy, Cancer, NCCN, Decision-making, Recurrence, DS, Squamous cell carcinoma, Prostate, Research, BMC, BMC Cancer, Journal of the National Comprehensive Cancer Network, Prognosis, Pancreas, SEER, Policy, USS William M. Wood (DE-287), Caregiver, Medicine, Twitter, Breast, Education, Veni, vidi, vici, Immunotherapy, Amazon (company), Farstad Shipping, Risk management, Dietary supplement, Medical imaging, Medical device, Silviculture, Vaccine, MD

PLYMOUTH MEETING, Pa., March 9, 2022 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers—today announced the publication of new NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Ampullary Adenocarcinoma. This evidence- and expert consensus-based resource follows the recent publication of new NCCN Guidelines® for Malignant Peritoneal Mesothelioma, bringing the total number of clinical guidelines to 83.

Key Points: 
  • PLYMOUTH MEETING, Pa., March 9, 2022 /PRNewswire/ --The National Comprehensive Cancer Network (NCCN)an alliance of leading cancer centerstoday announced the publication of new NCCN Clinical Practice Guidelines in Oncology ( NCCN Guidelines ) for Ampullary Adenocarcinoma .
  • NCCN Guidelines are available free-of-charge for non-commercial use at NCCN.org or via the Virtual Library of NCCN Guidelines App .
  • Newly-posted NCCN Guidelines for Patients: Systemic Mastocytosis (a rare mast cell disorder) and updated NCCN Guidelines for Patients: Small Cell Lung Cancer are available as a free download at NCCN.org/patientguidelines or the NCCN Patient Guides for Cancer App , or printed for a nominal fee via Amazon.com.
  • The National Comprehensive Cancer Network ( NCCN ) is a not-for-profit alliance of leading cancer centers devoted to patient care, research, and education.